PMOS replaces PCOS as new name for common women's endocrine disorder

International medical organizations announced in 2026 that Polycystic Ovary Syndrome (PCOS) will be renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change reflects growing evidence that the condition involves endocrine and metabolic dysfunction beyond ovarian cysts, including insulin resistance, type‑2 diabetes risk, cardiovascular issues, and mental‑health challenges.

The new terminology was driven by a large survey of 14,000 patients and health professionals and aims to improve diagnostic clarity, reduce stigma and guide research toward the metabolic roots of the disorder. About 170 million women worldwide—roughly 13 % of the female population—are estimated to be affected. While many clinicians and advocates welcome the update, some critics argue that resources could have been directed toward research rather than rebranding.

Treatment for PMOS continues to focus on lifestyle interventions, hormone‑balancing medications and mental‑health support, but the name change is expected to promote earlier detection and more targeted therapies.